Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGILE 3b
PACTR202605916782556Phase 1Completed
- Sponsor
- University of Liverpool
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of nitazoxanide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Liverpool. Primary endpoints: Safety and tolerability and Virological efficacy. Started Jul 2021; status: completed.
02
Drugs
nitazoxanide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202605916782556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605916782556.